Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 29% Improvement Relative Risk c19early.org/d Baktash et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Prospective study of 70 patients in the United Kingdom Lower mortality with higher vitamin D levels (not stat. sig., p=0.5) Baktash et al., Postgraduate Medical J., doi:10.1136/postgradmedj-2020-138712 Favors vitamin D Favors control
Vitamin D status and outcomes for hospitalised older patients with COVID-19
Baktash et al., Postgraduate Medical Journal, doi:10.1136/postgradmedj-2020-138712
Baktash et al., Vitamin D status and outcomes for hospitalised older patients with COVID-19, Postgraduate Medical Journal, doi:10.1136/postgradmedj-2020-138712
Aug 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective study of 105 hospitalized patients, showing lower vitamin D levels in the COVID-19 positive group (27.0 nmol/L vs 52.0 nmol/L, p=0.0008), and non-statistically significant higher mortality with vitamin D deficiency.
risk of death, 28.6% lower, RR 0.71, p = 0.50, high D levels 4 of 31 (12.9%), low D levels 6 of 39 (15.4%), adjusted per study, inverted to make RR<1 favor high D levels, >30nmol/L.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Baktash et al., 27 Aug 2020, prospective, United Kingdom, peer-reviewed, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Vitamin D status and outcomes for hospitalised older patients with COVID-19 Vadir Baktash,1 Tom Hosack,1 Nishil Patel,1 Shital Shah,1 Pirabakaran Kandiah,1 Koenraad Van Den Abbeele,1 Amit K J Mandal ,1 Constantinos G Missouris1,2 1 Department of Medicine, Frimley Health NHS Foundation Trust, Wexham Park Hospital, Slough, UK 2 Department of Cardiology, University of Cyprus Medical School, Nicosia, Cyprus Correspondence to Constantinos G Missouris, Department of Medicine, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Wexham Street, Slough, UK; dinos.mis souris@nhs.net Received 18 July 2020 Accepted 1 August 2020 Revised 1 August 2020 ABSTRACT Purpose Older adults are more likely to be vitamin D deficient. The aim of the study was to determine whether these patients have worse outcomes with COVID-19. Methods We conducted a prospective cohort study between 1 March and 30 April 2020 to assess the importance of vitamin D deficiency in older patients with COVID-19. The cohort consisted of patients aged ≥65 years presenting with symptoms consistent with COVID-19 (n=105). All patients were tested for serum 25hydroxyvitamin D (25(OH)D) levels during acute illness. Diagnosis of COVID-19 was confirmed via viral reverse transcriptase PCR swab or supporting radiological evidence. COVID-19-positive arm (n=70) was sub-divided into vitamin D-deficient (≤30 nmol/L) (n=39) and -replete groups (n=35). Subgroups were assessed for disease severity using biochemical, radiological and clinical markers. Primary outcome was in-hospital mortality. Secondary outcomes were laboratory features of cytokine storm, thoracic imaging changes and requirement of non-invasive ventilation (NIV). Results COVID-19-positive arm demonstrated lower median serum 25(OH)D level of 27 nmol/L (IQR=20–47 nmol/L) compared with COVID-19-negative arm, with median level of 52 nmol/L (IQR=31.5–71.5 nmol/L) (p value=0.0008). Among patients with vitamin D deficiency, there was higher peak D-dimer level (1914.00 μgFEU/L vs 1268.00 μgFEU/L) (p=0.034) and higher incidence of NIV support and high dependency unit admission (30.77% vs 9.68%) (p=0.042). No increased mortality was observed between groups. Conclusion Older adults with vitamin D deficiency and COVID-19 may demonstrate worse morbidity outcomes. Vitamin D status may be a useful prognosticator.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit